source
- Roche pays $190 million for rights to Hanmi's UCN2 analog targeting obesity with muscle-preserving effectsRoche's Genentech unit has agreed to pay $190 million upfront for rights to HM17321, a urocortin‑2 analog developed by South Korea’s Hanmi Pharmaceutical, covering markets outside South Korea. The…
- Genentech pays $45M upfront to DualityBio for ADC platform targeting resistant cancersGenentech has agreed to pay DualityBio $45 million upfront for rights to its antibody‑drug conjugate (ADC) technology, with the agreement offering more than $1 billion in potential milestone paymen…Fierce Biotech · 13d agoDealPositive